Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary Fibrosis

Update Il y a 4 ans
Reference: EUCTR2016-003473-17

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the effect of CC-90001, 200 mg and 400 mg, when orally administered (PO) once daily (QD), compared with placebo, on percent of predicted forced vital capacity (FVC) after 24 weeks of treatment in subjects with IPF.


Inclusion criteria

  • Idiopathic pulmonary fibrosis

Links